TIDMAKT
RNS Number : 2502X
Ark Therapeutics Group PLC
06 February 2013
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Identity of the party to the offer making the disclosure: Ark Therapeutics Group plc
(b) Owner or controller of interests and short positions disclosed, if different from N/A
1(a):
The naming of nominee or vehicle companies is insufficient
---------------------------
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Ark Therapeutics Group plc
Use a separate form for each party to the offer
---------------------------
(d) Is the party to the offer making the disclosure the offeror or the offeree? Offeree
---------------------------
(e) Date position held: 6 February 2013
---------------------------
(f) Has the party previously disclosed, or is it today disclosing, under the Code in NO
respect
of any other party to this offer?
---------------------------
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates
Class of relevant security: Ordinary shares of 1p each
Interests Short positions
---------------- ------------------
Number % Number %
--------- ----- ------------ ----
(1) Relevant securities owned and/or controlled: None N/A None N/A
--------- ----- ------------ ----
(2) Derivatives (other than options): None N/A None N/A
--------- ----- ------------ ----
(3) Options and agreements to purchase/sell: None N/A None N/A
--------- ----- ------------ ----
None N/A None N/A
TOTAL:
--------- ----- ------------ ----
All interests and all short positions should be disclosed.
Details of any open derivative or option positions, or
agreements to purchase or sell relevant securities, should be given
on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: None
Details, including nature of the rights concerned and relevant percentages: N/A
-----
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(c) Irrevocable commitments and letters of intent
Details of any irrevocable commitments or letters of intent procured by the party to the offer
making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of
the Code):
None
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe of any person acting in
concert with the party to the offer making the disclosure:
WG Partners LLP, a trading name of Charles Stanley & Co. Ltd (Financial Adviser to Ark Therapeutics
Group plc) - 767,765 ordinary shares of 1p each representing 0.37% of the total issued share
capital of Ark Therapeutics Group plc.
3.1 Shares held by the directors of Ark Therapeutics Group plc
Name of director Number of shares Percentage of issued
share capital
Professor S Ylä-Herttuala 3,162,835 1.51
----------------- ---------------------
D Prince 16,486 0.01
----------------- ---------------------
Dr D Bloxham 273,972 0.13
----------------- ---------------------
I Ross *822,000 0.39
----------------- ---------------------
C Spicer **551,395 0.26
----------------- ---------------------
* Held through Mr. Ross' Self Invested Pension Plan ("SIPP")
** Held through Mr. Spicer's SIPP
3.2 Rights to subscribe for shares in Ark Therapeutics Group plc
Name of Date of Earliest Expiry date Exercise Options
director grant exercise price held over
date (GPB (GBP)) number
of shares
D Prince 26/05/2004 26/05/2005 **26/05/2014 GBP1.33 150,000
------------ ------------ ------------------ ------------- -----------
Professor
S Ylä-Herttuala 24/09/2003 24/09/2004 *23/09/2013 50.00p 50,000
------------ ------------ ------------------ ------------- -----------
29/01/2004 28/01/2005 *27/01/2014 60.50p 50,000
------------ ------------ ------------------------------------------ ------------- -----------
28/09/2004 28/09/2004 31/12/2014 60.00p 99,999
------------ ------------ ------------------------------------------ ------------- -----------
12/03/2005 12/03/2008 ***11/03/2015 96.25p 50,000
------------ ------------ ------------------------------------------ ------------- -----------
04/01/2006 04/01/2009 ***03/01/2016 GBP1.04 50,000
------------ ------------ ------------------------------------------ ------------- -----------
03/01/2007 03/01/2010 ****02/01/2017 94.75p 16,500
------------ ------------ ------------------------------------------ ------------- -----------
03/01/2008 03/01/2011 ****02/01/2018 94.00p 13,998
------------ ------------ ------------------------------------------ ------------- -----------
05/01/2009 05/01/2012 ****04/01/2019 39.25p 70,000
------------ ------------ ------------------------------------------ ------------- -----------
I Ross 10/09/2010 09/09/2012 *****08/09/2015 11.55p 2,000,000
------------ ------------ ------------------ ------------- -----------
17/04/2012 17/04/2015 ******16/04/2022 3.5p 2,000,000
------------ ------------ ------------------------------------------ ------------- -----------
Dr D Venables 17/04/2012 17/04/2015 ******16/04/2022 3.5p 5,000,000
------------ ------------ ------------------ ------------- -----------
* Exercisable over four years in equal instalments.
** Exercisable over three years in equal instalments.
*** Vest, subject to performance conditions, over four years in
equal instalments: exercisable after three years
**** Vest, subject to performance conditions, over three years:
exercisable after three years
***** 1/24(th) vest at the end of each successive calendar month
after 9/9/10 and until and including September 2012. Exercisable
from 9/9/12 to 8/9/15
****** Vest in three equal tranches on the third, fourth and
fifth anniversaries of the date of grant, but will only be
exercisable if the share price on the exercise date is at least
twice the exercise price at the date of grant.
Included in the preceding table are retained options held by
Professor S Ylä-Herttuala over shares in Ark Therapeutics Limited,
but, under an agreement dated 12 July 2002 between Ark Therapeutics
Limited, Ark Therapeutics Group plc and Professor S Ylä-Herttuala,
on any exercise of these options Ark Therapeutics Limited shares
subject to option shall be issued directly to Ark Therapeutics
Group plc and Ark Therapeutics Group plc shall issue the equivalent
number of its shares to Professor S Ylä-Herttuala.
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 3 for each additional class of
relevant security.
Details of any open derivative or option positions, or
agreements to purchase or sell relevant securities, should be given
on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the party to the offer making the disclosure or any person acting
in concert with it:
If there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the party
to the offer making the disclosure, or any person acting in concert with it, and any other
person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
Supplemental Form 8 (SBL) NO
---
Date of disclosure:
6 February 2013
Contact name: Sue Steven
--------------------
Telephone number: +44 (0)20 7388 7722
--------------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the
Code's dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FEENKADKDBKDDBK
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From May 2024 to Jun 2024
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jun 2023 to Jun 2024
